Neutrophil/lymphocyte ratio and mean platelet volume in branch retinal vein occlusion  by Turkseven Kumral, Esra et al.
Saudi Journal of Ophthalmology (2016) 30, 105–108Original ArticleNeutrophil/lymphocyte ratio and mean platelet volume
in branch retinal vein occlusionPeer review under responsibility
of Saudi Ophthalmological Society,
King Saud University Production and hosting by Elsevier
Access this article onlin
www.saudiophthaljourn
www.sciencedirect.com
Received 21 June 2015; received in revised form 16 October 2015; accepted 9 February 2016; available online 16 February 2016.
Haydarpasa Numune Training and Research Hospital, Tıbbiye Cad. No: 40 34668 Üsküdar, _Istanbul, Turkey
⇑ Corresponding author. Tel.: +90 (216)5423232/5423200; fax: +90 (216) 336 05 65.
e-mail address: ophserhat@hotmail.com (S. Imamoglu).Esra Turkseven Kumral; Nursal Melda Yenerel; Nimet Yesim Ercalik; Serhat Imamoglu ⇑; Ece Turan VuralAbstractPurpose: To evaluate the mean platelet volume (MPV) and the neutrophil/lymphocyte ratio (NLR) in patients with branch retinal
vein occlusion (BRVO).
Methods: Thirty patients with branch retinal vein occlusion (BRVO group) and 27 age and sex matched subjects (control group)
were included in the study. MPV and NLR parameters obtained from peripheral blood were recorded.
Results: The mean age was 62.6 ± 12.3 years in BRVO and 63.5 ± 8.2 years in control group. The BRVO group consisted of 13
males and 17 females and the control group included 12 male and 15 female subjects. The mean MPV values were 8.64 ± 2.01
fL in BRVO group and 8.5 ± 1.26 fL in control group. NLR was 2.24 ± 0.79 and 1.89 ± 0.64 in BRVO and control groups respec-
tively. The difference between two groups in terms of MPV and NLR was not statistically significant.
Conclusion: MPV and NLR were found to be not affected in branch retinal vein occlusion patients.
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Diabetic retinopathy is the most common retinal vascu-
lopathy. Retinal vein occlusions (RVO) make up the second
most common category.1 It is estimated that 16.4 (95% CI
13.9–18.9) million people in the world have RVO.2 Branch
retinal vein occlusions (BRVO) constitute 69.5% of the RVOs.3
Although the pathogenesis of RVO is not clearly understood,
it is believed that Principles of Virchow’s triad for thromboge-
nesis including abnormalities of the vessel wall, alterations in
the blood, and alterations in the blood flow are responsible.4
Degenerative changes in the vessel walls seem to be the
most important one5 and primarily arteriovenous crossings
are the sites of occlusion.6 Only 4.9% of cases have an occlu-
sion other than an arteriovenous crossing and some other
factors such as inflammation (e.g., in sarcoidosis) are thoughtto be responsible.7,8 Hypertension, diabetes mellitus, dyslipi-
demia, cigarette smoking, cardiovascular and renal disease
are the risk factors for BRVO.9
Neutrophil/lymphocyte ratio (NLR) and mean platelet vol-
ume (MPV) as inflammatory markers recently became popular
because of their simplicity, cost effectivity and their advan-
tages to predict clinical prognosis of specific diseases.10
Platelets have an important role in the pathogenesis of
thrombo-occlusive diseases. Alterations in the platelet func-
tion and morphology are determined primarily during or
before the fragmentation of their precursor cell (megakary-
ocyte).11 Megakaryocyte development has a correlation with
the process of nuclear polyploidization.12 Ploidy may change
with platelet consumption and destruction. As megakary-
ocyte ploidy increases, larger and more active platelets are
produced.13 Larger and activated platelets produce moree:
al.com
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activation. Ozkan et al. found a relationship between myocar-
dial _Infarction and MPV values.14
White blood cell (WBC) count is readily used as an inflam-
matory marker. However, ratios of subtypes of WBC change
during an inflammatory response. NLR is more stable than
any other WBC subtypes such as neutrophil, lymphocyte and
total leukocyte counts. Thus NLR has become an important
biomarker to determine inflammation in cardiac disorders.15
As branch retinal vein occlusion is a disease that goes with
thrombosis and inflammatory processes, these inflammatory
markers could help us to predict the risk of RVO. In this study
we aimed to investigate a link between NLR and MPV param-
eters and BRVO.
This study is adhered to the tenets of the Declaration of
Helsinki and was approved by the Institutional Review Board
of the Department of Ophthalmology, Haydarpasa Numune
Training and Research Hospital, Turkey, and informed con-
sent was obtained to participate in the study.Table 1. Comparison of laboratory data between BRVO and control group.Materials and methods
Thirty patients with recently diagnosed branch retinal vein
occlusion (BRVO group) and 27 age and sex matched sub-
jects (control group) were included in the study. All patients
underwent full ophthalmologic evaluation including best cor-
rected visual acuity, pupillary reactions, intraocular pressure
measurement, biomicroscopic and fundoscopic examination.
Hemorrhages, cotton wool-spots, edema, and venous dilata-
tion and tortuosity arise from arteriovenous crossing seen in a
localized retinal area was diagnosed as branch retinal vein
occlusion. Patients with signs of an acute stage of BRVO
within a week and no history of previous treatment were
included in the study.
All patients with BRVO had systemic hypertension that
was under control by medication. Patients with glaucoma,
diabetes, systemic inflammatory diseases, cardiovascular,
hepatic and renal disorders, blood dyscrasias, and malig-
nancy were excluded from the study. History of routine
anti-inflammatory drug usage, oral contraceptives and anti-
coagulants, smoking and alcohol consumption was also
included in exclusion criteria as they might affect thrombosis.
Blood samples for complete blood count (CBC) were
obtained between 08:00 and 9:00 a.m. after overnight fasting
from the antecubital vein. Venous blood (1.8 ml) was col-
lected and mixed with 0.2 ml 3.8% sodium citrate solution
and analyzed within 2 h after sampling with Cell-Dyn 3700
Hematology Analyzer (Cell-Dyn 3700, Abbott Diagnostics,
Abbott Park, IL, USA). It performs simultaneous laser and
impedance measurements. The NLR was calculated by divid-
ing the neutrophil count by the lymphocyte count and MPV
by dividing platelet crit (PCT) by the total number of
platelets.BRVO (n = 30) Control (n = 27) p
Mean ± SD Mean ± SD
Hb (g/dL) 13.35 ± 1.22 12.78 ± 1.15 0.10
Htc (%) 39.56 ± 3.21 38.57 ± 3.48 0.31
Plt (K/lL) 268.27 ± 57.13 247.69 ± 54.85 0.21
Ptc 0.23 ± 0.06 0.21 ± 0.06 0.13
MPV (fL) 8.64 ± 2.01 8.5 ± 1.26 0.10
NLR 2.24 ± 0.79 1.89 ± 0.64 0.30
Hb, hemoglobin; Htc, hematocrit; Plt, platelet count; Pct, platelet crit; SD, standard
deviation; p > 0.05.Statistical analysis
Statistical analysis was done by SSPS statistical software
(SPSS for windows 17.0, Inc., Chicago, IL, USA). Parametric
Student’s t-test and nonparametric Mann-Whitney’s U test
were used for comparison of independent groups. Data were
reported as mean ± standard deviation (±SD). A level of
P < 0.05 was considered significant.Results
The BRVO group consisted of 13 male and 17 female
patients and the control group included 12 male and 15
female subjects. The mean age of the BRVO group was
62.60 ± 12.3 years and the control group was 63.50 ±
8.20 years. There was not a statistically significant difference
between groups with regard to age and sex. The mean MPV
values were 8.64 ± 2.01 fL in BRVO group and 8.5 ± 1.26 fL in
control group. The difference between two groups was not
statistically significant (p = 0.10, p > 0.05). NLR was
2.24 ± 0.79 and 1.89 ± 0.64 in BRVO and control groups
respectively. Statistically significant difference was not found
between two groups (p = 0.30, p > 0.05). There was no statis-
tically significant difference in platelet count and PCT
between groups (Table 1). There was also no statistically sig-
nificant difference between groups in terms of MPV cate-
gories (Table 2).Discussion
We investigated the importance of MPV and NLR values in
branch retinal vein occlusion and did not find any difference
in MPV and NLR values between BRVO and control group.
Retinal vein occlusion is the most common retinal vascular
pathology after diabetic retinopathy.16 BRVO is more com-
mon than CRVO. It is estimated that 5.6 times as many per-
sons are affected by BRVO compared to CRVO.2. It is
believed that cascades of thrombosis and inflammation play
role in the pathogenesis of BRVO.17
Some studies reported the relation between retinal vein
occlusion and thrombotic diseases such as hyperhomo-
cystinemia, factor V Leiden mutation, deficiency in protein
C or S, and anticardiolipin antibodies.18–20 Systemic inflam-
matory diseases are also involved in the pathogenesis of reti-
nal vein occlusion such as sarcoidosis and Behçet’s
disease.21,22 MPV and NLR are inflammatory markers for
the diseases related to thrombosis and inflammation. Etfal
et al. found that NLR as an inflammatory marker increases
in venous thromboembolism (VTE) and as the extent of VTE
increases, NLR increases too. They claimed that inflammatory
processes have an important role in prothrombotic state in
patients with VTE.10
MPV is thought to be a marker of platelet activation. It
increases with active and large platelets and is used as
laboratory test to predict some occlusive diseases. Elevated
MPV was found in silent cerebral infarction that may be an
indicator of transient ischemic attack or clinically unde-
tectable stroke.23 Also, increased MPV is linked with diseases
Table 2. Comparison of BRVO and control group by categories of mean
platelet volume.
Categories of MPV (fL) Groups Mean ± SD p
MPV < 9.5 BRVO (n = 18) 7.84 ± 0.77 0.57
Control (n = 22) 7.89 ± 0.71
MPV > 9.5 BRVO (n = 12) 10.63 ± 0.71 0.80
Control (n = 5) 10.45 ± 0.17
BRVO, branch retinal vein occlusion; MPV, mean platelet volume; SD, standard
deviation; p > 0.05.
Inflammatory Markers in Retinal Vein Occlusion 107associated with chronic inflammation such as hypertension
and diabetes mellitus.24,25 In recent studies, a link between
MPV values and retinal vein occlusion was reported. Sahin
et al. showed higher levels of MPV in patients with RVO.26
Önder et al. found higher MPV levels in hypertensive BRVO
patients.27
The present study showed no relation between BRVO and
NLR and MPV values. When the pathogenesis of BRVO is
took into consideration the most important predisposing fac-
tor is the sclerosis of the vessel wall and basement membrane
thickening, as it may occur with aging, hypertension, and dia-
betes.28 Arteriosclerotic hypertrophy of the neighboring
arterial wall causes compression of the involved vein where
the artery and vein share a common sheath.29 Compression
of the vein causes increased retinal venous blood flow veloc-
ity, turbulence of blood flow, endothelial injury, and sec-
ondary thrombosis.30 Thrombosis and inflammation have
less effect on pathogenesis of retinal vein occlusion. Ingerslev
stated that there is no need for a complete hematologic
investigation in RVO patients.31 Ornek et al. did not find
increased MPV values in patients with RVO compared to
controls.32 These inflammatory markers might be useful to
predict predisposition for venous thromboembolism in some
certain inflammatory and hematologic diseases other than
BRVO.
Elevated MPV was noted in diseases associated with arte-
rial and venous thrombosis, such as mitral stenosis and
dilated cardiomyopathy.33,34 Braekkan et al. investigated
the impact of MPV on the incidence of VTE and stated that
an increasing MPV is a predictor for VTE. They also found
age and sex adjusted higher risk of VTE in subjects with
MPV > 9.5 fL as compared to the subjects with PMV < 8.5
fL.35 As our study population was small MPV variables
categorized into >9.5 and <9.5 fL, no statistically significant
difference was found between groups in regard to MPV cat-
egories (Table 2).
There are some limitations in the study. The small cohort
of patients included might have influenced the statistical sig-
nificance. BMI of patients was not recorded and taken into
consideration as it has an effect on MPV values.
In conclusion, our study showed that MPV and NLR could
not be used as predictory markers for BRVO. Further studies
should be done to understand the efficiency of these markers
in the prediction and prognosis of BRVO.Conflict of interest
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